# Auto Review: results.txt

Generated: 2026-04-29 00:40
Reviewer: Qwen2.5-32B-Instruct-AWQ (auto_review.py)

## Summary

- **Samples**: 30
- **Clean**: 0/30
- **P0** (hallucination): 0
- **P1** (major error): 10
- **P2** (minor issue): 149

### Critical Issues

- **ROW 7** [P1]: Inaccurate staging information. The correct stage is pT3 N1, not Stage II-III.
- **ROW 14** [P1]: The sentence does not specify that the tumor is of duodenal origin, which is important information.
- **ROW 15** [P1]: Contradiction with the note. The note states concern about exposing the patient to additional oxaliplatin, yet the extracted data incorrectly states 'Continue/start: oxaliplatin'.
- **ROW 21** [P1]: Incomplete sentence, missing critical information about the specific dose reduction.
- **ROW 31** [P1]: Missing cancer-related medication (gemcitabine).
- **ROW 36** [P1]: Incomplete sentence with missing critical information (dose number).
- **ROW 40** [P1]: Incomplete sentence with missing critical information (lacks the specific dose increase).
- **ROW 43** [P1]: Incomplete sentence with missing critical information. The sentence mentions 'slowly declining' but does not clarify the trend clearly.
- **ROW 72** [P1]: Missing cancer-related medication (gemcitabine and Abraxane)
- **ROW 90** [P1]: Incomplete sentence with missing critical information.

---

## ROW 1 — ⚠️ ISSUES

**Type**: Moderately differentiated pancreatic adenocarcinoma
**Stage**: Potentially resectable with a regional LN involvement

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (palonosetron). | He initiated ***** on 03/06/2022, once his LFTs had sufficiently normalized post-stent, and is now s |
| P2 | Lab_Results | Missing initial CA 19-9 value (77,736). | Baseline *****-9 markedly elevated at 77,736 (in the context of obstructive jaundice) |
| P2 | Treatment_Changes | Missing mention of palonosetron. | He initiated ***** on 03/06/2022, once his LFTs had sufficiently normalized post-stent, and is now s |
| P2 | Treatment_Goals | Inaccurate goal description. Should include 'potentially curative' rather than just 'curative'. | We reviewed his most recent imaging studies which show, quite encouragingly, resolution of his aorto |
| P2 | Response_Assessment | Missing mention of the drop in CA 19-9 from 77,736 to 6,105. | Baseline *****-9 markedly elevated at 77,736 (in the context of obstructive jaundice) |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing specific cancer-related medications and lab results.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 4 — ⚠️ ISSUES

**Type**: Metastatic pancreatic ductal adenocarcinoma
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine-based regimen mentioned as a potential future treatment). | We talked about potential side fx and risks, esp in terms of infectious complications, and adverse i |

*Extraction summary*: Most fields are clean, but 'Current_Medications' is missing a potential future cancer-related treatment.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained jargon 'peritoneal carcinomatosis'. | Additionally, the peritoneal carcinomatosis has slightly worse large volume asci |
| P2 | Unexplained jargon 'pancolitis'. | There is no evidence of bowel obstruction, and pancolitis has nearly resolved wi |

*Letter summary*: Letter contains minor readability issues due to unexplained medical jargon.

---

## ROW 6 — ⚠️ ISSUES

**Type**: Pancreatic neuroendocrine tumor, grade 2
**Stage**: now metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Type_of_Cancer | The note mentions both grade 1 and grade 2, but the extracted data only states grade 2. | Pathology(+) 5.5cm well-differentiated neuroendocrine tumor, grade 1 (ki-67% <2%)... *****-67: 19.7% |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note does not specify a stage, but the extracted data states 'now metastatic'. | Patient presents for follow up of recurrent grade 1 pancreatic neuroendocrine tumor. |
| P2 | Clinical_Findings.findings | The extracted data does not mention the patient's ECOG PS 0, which is mentioned in the note. | Physical exam shows no palpable masses, jaundice, ascites, or significant weight loss. Patient is EC |
| P2 | Procedure_Plan.procedure_plan | The extracted data includes '[REDACTED]' which is not clear and could be improved. | Future options include liver directed therapy, everolimus, tumors are very dotatoc avid, suggesting  |

*Extraction summary*: Most fields are clean, but there are minor issues with the cancer grade, stage specification, ECOG PS, and use of [REDACTED].

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | The term 'lymph nodes' is used without explanation, which may be jargon for an 8th-grade reading level. | Imaging findings show that the cancer in your liver and lymph nodes has grown si |
| P2 | The term 'MRI' is used without explanation, which may be jargon for an 8th-grade reading level. | MRI scans will be used to monitor the tumor's progress. |

*Letter summary*: Letter is mostly clean but contains minor readability issues with unexplained medical terms.

---

## ROW 7 — ⚠️ ISSUES

**Type**: Well-differentiated pancreatic ductal adenocarcinoma
**Stage**: pT3 N1

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. The note mentions metformin, methylphenidate, ondansetron, and oxycodone, but only ondansetron and oxycodone are listed under supportive_meds. However, only cancer-related medications should be included in current_meds. | Medications the patient states to be taking prior to today's encounter. METFORMIN HCL (METFORMIN ORA |
| P2 | Treatment_Changes | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Treatment_Goals | Inaccurate. The goal is adjuvant therapy, not curative. The note mentions that the patient is receiving adjuvant chemotherapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Response_Assessment | Inaccurate. The response assessment should include the patient's current condition and the absence of disease recurrence, not just the improvement in labs. | The patient's labs are noted to be significantly improved, allowing continuation of gemcitabine. The |
| P2 | Medication_Plan | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Therapy_plan | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |

*Extraction summary*: Most fields are clean, but there are minor issues with completeness and accuracy in medication and treatment plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate staging information. The correct stage is pT3 N1, not Stage II-III. | You have a well-differentiated pancreatic ductal adenocarcinoma (cancer that sta |
| P2 | Unexplained jargon 'labs'. | Your labs are noted to be significantly improved, allowing continuation of gemci |
| P2 | Unexplained jargon 'adjuvant chemotherapy', 'cumulative peripheral sensory neuropathy'. | You are currently receiving adjuvant chemotherapy with gemcitabine alone, having |

*Letter summary*: The letter contains inaccuracies and minor readability issues.

---

## ROW 14 — ⚠️ ISSUES

**Type**: High-grade neuroendocrine tumor of duodenal/ampullary origin
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Only 'capecitabine' is listed, while 'temozolomide' is also a cancer-related medication. | She is now s/p 5 cycles of chemotherapy consisting of the combination of capecitabine/temozolomide. |

*Extraction summary*: One minor issue found in Current_Medications. All other fields are clean.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The sentence does not specify that the tumor is of duodenal origin, which is important information. | You came in for a follow-up visit regarding your neuroendocrine tumor treatment. |
| P2 | The term 'fluid buildup' might be confusing; 'ascites' is more precise. | During the physical exam, no masses, fluid buildup, or enlarged liver were found |
| P2 | This sentence is incomplete as it doesn't mention the dosing or frequency, though these details are intentionally omitted. | You will continue to take ondansetron and oxycodone to manage side effects. |
| P2 | The sentence lacks the detail about arranging for post-CT IV hydration. | After this cycle, you will have a CT scan with IV contrast to assess your tumor. |

*Letter summary*: The letter contains some inaccuracies and omissions that need addressing.

---

## ROW 15 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Distant Metastasis | Inaccurate specification of distant metastasis sites. Note mentions metastasis to celiac lymph nodes initially and later to liver and peritoneum, but the extracted data only lists liver and peritoneum. | At that time, he presented with back pain and a 15 pound weight loss. His metastatic disease at the  |
| P2 | Treatment_Changes.recent_changes | Inconsistent use of [REDACTED] placeholder. The note specifies resuming a specific treatment, but the exact name is redacted. The extracted data should maintain consistency with the note. | We will resume [REDACTED]. He responded initially quite well to [REDACTED] but because of his residu |
| P1 | Therapy_plan.therapy_plan | Contradiction with the note. The note states concern about exposing the patient to additional oxaliplatin, yet the extracted data incorrectly states 'Continue/start: oxaliplatin'. | He responded initially quite well to [REDACTED] but because of his residual neuropathy, I am concern |

*Extraction summary*: Most fields are clean, but there are minor issues with the specification of metastasis sites and inconsistent use of [REDACTED], and a major error in the therapy plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained jargon (oxaliplatin). | We will resume a medication. You responded initially quite well to a medication  |
| P2 | Unexplained jargon (omental, peritoneal metastases, ascites). | The cancer is showing progression with extensive peritoneal disease as evidenced |

*Letter summary*: Letter has minor readability issues due to unexplained medical jargon.

---

## ROW 17 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine and capecitabine). | She has now had 4 full cycles and returns today for follow-up imaging. When we last saw her, she had |
| P2 | Treatment_Changes | Missing ongoing chemotherapy (gemcitabine and capecitabine). | She will continue on chemotherapy without dose or schedule modification and we will also start denos |
| P2 | Imaging_Plan | Inaccurate imaging plan, should include both CT Chest and CT Abdomen/Pelvis. | She will continue on chemotherapy without dose or schedule modification and we will also start denos |

*Extraction summary*: Most fields are clean, but there are minor issues regarding missing ongoing chemotherapy and an inaccurate imaging plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 18 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma, grade 2; Intra-ampullary papillary-tubular neo
**Stage**: Originally Stage IB, now metastatic (pt2n0)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications. | Medication Instructions section lists general medications only. |
| P2 | Treatment_Changes | Supportive medications listed are not fully comprehensive. | Supportive medications mentioned are ondansetron, prochlorperazine, and loperamide, but others like  |
| P2 | Treatment_Goals | Goals of treatment are labeled as 'palliative', but the note suggests a mix of palliative and possibly curative intent. | The note discusses various treatment options including chemotherapy and clinical trials, suggesting  |
| P2 | Response_Assessment | The response assessment mentions a recent bump in CA 19-9 levels, but the exact value is not provided. | CA 19-9 level is mentioned as having increased, but the specific value is not given. |
| P2 | Medication_Plan | Specific drug names are [REDACTED], leading to incomplete information. | Future systemic treatment options are described but specific drug names are [REDACTED]. |
| P2 | Therapy_plan | Specific drug names are [REDACTED], leading to incomplete information. | Future systemic therapy options are described but specific drug names are [REDACTED]. |
| P2 | Procedure_Plan | Specific procedure name is [REDACTED], leading to incomplete information. | Will refer to Rad Onc team for assessment of candidacy for [REDACTED] of his dominant lung lesions. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications, incomplete supportive medication listing, and partially redacted drug names/procedures.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 21 — ⚠️ ISSUES

**Type**: Metastatic pancreatic cancer
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (5-FU/LV + irinotecan) | On this basis, he initiated 2nd-line chemotherapy consisting of the combination of 5-*****/LV plus * |
| P2 | Treatment_Changes | Missing detail about dose reduction of 5-FU/LV + irinotecan | Due to obstipation and anorexia following cycle #1, his doses were reduced by 20% beginning with cyc |
| P2 | Treatment_Goals | Incomplete — should include 'symptom management' | Therefore we had a ***** goals of care discussion in which I recommended that he refocus his goals p |
| P2 | Response_Assessment | Incomplete — should mention the decline in performance status | his declining performance status warranted holding of planned cycle #4 |
| P2 | Medication_Plan | Incorrect — should state 'hold' instead of 'continue/start' | his declining performance status warranted holding of planned cycle #4 |
| P2 | Therapy_plan | Incorrect — should state 'hold' instead of 'continue/start' | his declining performance status warranted holding of planned cycle #4 |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing cancer-related medications, incomplete treatment changes, and incorrect therapy plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence, missing critical information about the specific dose reduction. | Your chemotherapy doses were reduced by 20% starting with cycle #2 due to side e |

*Letter summary*: Letter contains an incomplete sentence regarding dose reduction.

---

## ROW 29 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | Inaccurate summary; mentions 'new diagnosis' instead of 'follow-up'. | This is an independent visit. |
| P2 | Current_Medications.current_meds | Incomplete; only lists Gemcitabine and Abraxane, but does not include other cancer-related medications like Zoledronic acid. | She elected to go on the ***** 301 trial. |
| P2 | Treatment_Changes.recent_changes | Incomplete; only lists Gemcitabine and Abraxane, but does not include other cancer-related medications like Zoledronic acid. | She elected to go on the ***** 301 trial. |
| P2 | Treatment_Changes.supportive_meds | Incomplete; includes only some supportive medications, missing others like Ritalin and Mirtazapine. | Continue Ritalin BID. Followed by SMS. Continue on Mirtazapine 115mg qHS. Followed by SMS. |
| P2 | Medication_Plan.medication_plan | Incomplete; does not include Ritalin and Mirtazapine. | Continue Ritalin BID. Followed by SMS. Continue on Mirtazapine 15mg qHS. Followed by SMS. |
| P2 | Therapy_plan.therapy_plan | Incomplete; does not include Ritalin and Mirtazapine. | Continue Ritalin BID. Followed by SMS. Continue on Mirtazapine 15mg qHS. Followed by SMS. |

*Extraction summary*: Most fields are clean, but there are minor issues with the summary, current medications, and supportive medications lists.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 31 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | Missing cancer-related medication (gemcitabine). | We initially saw him two months ago. Because of his comorbidities and poor performance status, we re |
| P2 | Treatment_Changes | Supportive medication listed incorrectly as a change. | prochlorperazine (COMPAZINE) 5 mg tablet Take 1 tablet (5 mg total) by mouth every 6 (six) hours as  |

*Extraction summary*: Major error in missing gemcitabine under current medications. Minor issue with listing prochlorperazine as a change.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained medical jargon (WBC, RBC, hemoglobin, hematocrit) | Your white blood cell count is high, and your red blood cell count, hemoglobin,  |
| P2 | Unexplained medical jargon (Cancer Antigen 19-9) | Additionally, your Cancer Antigen 19-9 level is very high. |

*Letter summary*: Letter contains minor readability issues due to unexplained medical jargon.

---

## ROW 32 — ⚠️ ISSUES

**Type**: Metastatic moderately differentiated adenocarcinoma of pancreatic or biliary ori
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications (gemcitabine, irinotecan, oxaliplatin, leucovorin) | The patient is inclined to move ahead with standard of care (SOC) chemotherapy with [REDACTED]. |
| P2 | Treatment_Changes | Supportive medications listed are not complete (missing growth factor support) | Supportive medications include primary prophylaxis with growth factor support ([REDACTED] or Neupoge |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications and incomplete listing of supportive medications.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained medical jargon 'metastases'. | You have a 6 cm irregular mass in the body of your pancreas with multiple liver  |
| P2 | Unexplained medical jargon 'growth factor support'. | Supportive medications include primary prophylaxis with growth factor support af |
| P2 | Unexplained medical jargon 'Mediport'. | You are scheduled to have a Mediport placed through your local oncologist. |

*Letter summary*: Letter contains minor readability issues related to unexplained medical jargon.

---

## ROW 33 — ⚠️ ISSUES

**Type**: Metastatic pancreatic adenocarcinoma with biopsy-proven liver metastasis
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medication (irinotecan). | She was started on ***** 06/07/19 and has been tolerating it well with dose reduction of irinotecan  |
| P2 | Treatment_Changes | Inconsistent mention of irinotecan. It states 'Switch to gemcitabine combined with nab-paclitaxel' without explicitly mentioning discontinuation of irinotecan. | my recommendation is to switch her therapy to gemcitabine combined with *****-paclitaxel. |
| P2 | Treatment_Goals | The goal 'palliative' is correct but the note suggests a more complex situation with ongoing management and switching treatments. | She has been tolerating it well with dose reduction of irinotecan by 20% starting with cycle 2. |
| P2 | Medication_Plan | Mentions irinotecan without specifying its discontinuation. | Continue irinotecan. Plan for gemcitabine 1000 mg/m2 + [REDACTED]-paclitaxel 125 mg/m2 on days 1, 8, |
| P2 | Therapy_plan | Mentions continuing irinotecan without specifying its discontinuation. | Continue irinotecan. Plan for gemcitabine 1000 mg/m2 + [REDACTED]-paclitaxel 125 mg/m2 on days 1, 8, |

*Extraction summary*: Most fields are clean, but there are minor issues regarding the inclusion of irinotecan in the current medications and therapy plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | The term 'enhancement' may be confusing to a layperson. | Recent imaging shows stable disease in the liver but progressive disease in the  |
| P2 | While 'Cancer Antigen 19-9' and 'Carcinoembryonic Antigen' are acceptable terms, they might still be confusing. | Your Cancer Antigen 19-9 and Carcinoembryonic Antigen levels remain high. |
| P2 | The term 'gemcitabine and nab-paclitaxel' might be confusing. | You will receive gemcitabine and nab-paclitaxel on days 1, 8, and 15 of a 28-day |

*Letter summary*: Letter contains minor readability issues that could be improved for clarity.

---

## ROW 35 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreatic tail with metastatic disease to liver
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions a biopsy revealing adenocarcinoma, suggesting the patient might be on initial cancer-related medications. | Biopsy of the pancreatic mass revealed adenocarcinoma. |
| P2 | Treatment_Changes | The field is empty, but the note discusses potential treatment plans and supportive medications. | The patient will receive antiemetics and anti-diarrheal medications prior to the initiation of chemo |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medication and treatment changes.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained jargon (EUS). | MRI and EUS tests showed a large pancreatic tumor and four liver tumors, suggest |
| P2 | Unexplained jargon (genetic counselor). | You will be referred to a genetic counselor to check for inherited cancer syndro |

*Letter summary*: Letter is mostly clean but contains minor readability issues related to unexplained medical jargon.

---

## ROW 36 — ⚠️ ISSUES

**Type**: Nonfunctioning pancreatic neuroendocrine tumor
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Everolimus is listed, but the note mentions multiple doses (2.5 mg and 10 mg). | everolimus (AFINITOR) 2.5 mg TAB 7.5 mg (3 tabs) daily  90 tablet  6    everolimus 10 mg TAB Take 1 |
| P2 | Treatment_Changes | Incomplete. The note mentions holding everolimus during partial SBO, but this detail is not fully captured. | Everolimus held during that period of time, resumed two weeks ago. |
| P2 | Treatment_Goals | Slightly imprecise. 'palliative' is correct, but 'durable disease control' might be a more precise term given the context. | with evidence of good durable disease control and reasonably good (in fact, improved) tolerance on c |
| P2 | Medication_Plan | Slightly imprecise. The note mentions starting non-insulin pharmacologic treatment in the future, but this is not clearly stated. | discussed potential plan to start non-insulin pharmacologic rx in the future. |

*Extraction summary*: Most fields are clean, but there are minor issues related to completeness and precision in medication details and treatment goals.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information (dose number). | Your dose of everolimus was reduced from 10 . This change was made in April 2012 |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 40 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications (gemcitabine and Abraxane) in the current medications section. | We recommend a course of treatment with gemcitabine and Abraxane. |

*Extraction summary*: One minor issue identified in the Current_Medications field.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information (lacks the specific dose increase). | We plan to increase the dose of your pain patch, and added Reglan and when neces |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 41 — ⚠️ ISSUES

**Type**: Invasive adenocarcinoma of pancreatic head, post-treatment tumor appears well- t
**Stage**: Not available (redacted), now with local recurrence

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication information. | He is continuing with an insulin regimen and regular use of enzyme supplements with meals. |
| P2 | Treatment_Changes | Missing recent treatment changes. | The patient received 12 cycles of neoadjuvant chemotherapy with essentially stable disease. |
| P2 | Imaging_Plan | Missing recommendation for PET/CT. | Further evaluation with PET/CT may be helpful for confirmation. |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing cancer-related medication information, recent treatment changes, and imaging recommendations.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained medical jargon 'CT scans' and 'liver lesion'. | Your recent CT scans show a decrease in size of a liver lesion, initially measur |
| P2 | Unexplained medical jargon 'soft tissue' and 'local recurrence'. | However, there is an increase in soft tissue near the surgical site, suggesting  |

*Letter summary*: Letter is mostly clean but contains minor readability issues related to unexplained medical jargon.

---

## ROW 43 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Borderline resectable pancreatic adenocarcinoma due to <180 degrees of vascular 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications. | The note mentions 'Continue to monitor [REDACTED] July 04 [REDACTED] 4 weeks.' and 'Continue [REDACT |

*Extraction summary*: Most fields are clean, but the current medications related to cancer treatment are missing.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. The sentence mentions 'slowly declining' but does not clarify the trend clearly. | Your CA 19-9 levels, a tumor marker, have fluctuated during treatment but are sl |

*Letter summary*: The letter contains a minor issue with an incomplete sentence that requires clarification.

---

## ROW 59 — ⚠️ ISSUES

**Type**: Well to moderately differentiated adenocarcinoma of the pancreas; Mucinous adeno
**Stage**: Likely advanced stage (likely or higher) due to positive retroperitoneal margin 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions several cancer-related medications such as propylthiouracil (PTU) for hyperthyroidism. | propylthiouracil (PTU) 50 mg tablet Take 25 mg by mouth. |
| P2 | Treatment_Changes | The field is empty, but the note mentions ongoing treatment for hyperthyroidism with propylthiouracil (PTU). | propylthiouracil (PTU) 50 mg tablet Take 25 mg by mouth. |
| P2 | Imaging_Plan | The field only mentions 'CT Chest', but the note suggests ongoing surveillance which may include other imaging modalities. | She will continue on surveillance. We'll see her again in 6 months. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications, treatment changes, and incomplete imaging plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | The sentence is vague and does not specify the type of cancer. | You came in for a follow-up visit regarding your cancer treatment. |
| P2 | The term 'groundglass nodule' may be confusing to a layperson. | A 6mm groundglass nodule in the left upper lobe of your lung remains unchanged s |

*Letter summary*: Letter is mostly clean but requires minor clarifications for accuracy and readability.

---

## ROW 62 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma
**Stage**: Originally pT3 N1, now metastatic (pt3 n1)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medication (abraxane). | We will cont ***** ***** abraxane. |
| P2 | Treatment_Changes | Missing detail about the specific drug started on 11/05/20. | Started ***** ***** 11/05/20 |
| P2 | Treatment_Goals | Inaccurate goal description. Should be 'palliative' but context suggests ongoing treatment for metastatic disease. | We will cont ***** ***** abraxane. |
| P2 | Response_Assessment | Inaccurate response assessment. Note mentions 'elevated tumor marker levels' but does not specify the trend over time. | Noted elevated tumor marker November 2019 |
| P2 | Medication_Plan | Missing detail about the specific drug plan (abraxane). | We will cont ***** ***** abraxane. |
| P2 | Therapy_plan | Missing detail about the specific drug plan (abraxane). | We will cont ***** ***** abraxane. |
| P2 | Imaging_Plan | Missing detail about the specific imaging plan (CT scan). | I will ask medical genetics to weigh in on the ***** of the ATM  ***** mutation and overlay this wit |
| P2 | Genetic_Testing_Plan | Missing detail about the specific genetic testing plan. | I will ask medical genetics to weigh in on the ***** of the ATM  ***** mutation and overlay this wit |

*Extraction summary*: Most fields are clean, but there are several minor issues regarding missing details about current medications, treatment plans, and imaging/genetic testing plans.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 72 — ⚠️ ISSUES

**Type**: Moderately differentiated adenocarcinoma of the pancreas
**Stage**: Originally borderline resectable, now metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | Missing cancer-related medication (gemcitabine and Abraxane) | We elected to start gemcitabine and Abraxane. He has now had almost 4 cycles. |
| P2 | Treatment_Changes | Inconsistent mention of recent changes; the note mentions resuming chemotherapy with reduced dose [REDACTED], but the plan is to continue with gemcitabine and Abraxane. |  |

*Extraction summary*: Major error in missing cancer-related medication and minor inconsistency in treatment changes.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Use of 'perilymphatic and interlobular septal nodularity' may be too complex for an 8th-grade reading level. | Your cancer is currently showing stable disease in the abdomen but progressing p |

*Letter summary*: Letter is mostly clean but contains some complex medical terminology that could be simplified further.

---

## ROW 77 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the tail of the pancreas
**Stage**: Resectable at diagnosis, now with negative margins and lymph nodes

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | Inaccurate summary of the visit. It mentions 'follow-up visit for adjuvant therapy with gemcitabine and capecitabine' which is incorrect as the patient has already completed 6 cycles of adjuvant therapy. | He has had 6 cycles and is on surveillance. |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage description is imprecise. The note does not provide a specific stage, only that it was resectable at diagnosis. | Because of renal and splenic invasion, the left kidney and left adrenal and spleen were included in  |
| P2 | Treatment_Changes.recent_changes | Missing recent treatment changes. The note states the patient has completed adjuvant therapy and is now on surveillance. | He has had 6 cycles and is on surveillance. |
| P2 | Treatment_Changes.supportive_meds | Missing supportive medications. The note does not mention any supportive medications, but the field should be explicitly stated as 'None'. | No outpatient medications have been marked as taking for the 09/16/20 encounter |
| P2 | Response_Assessment.response_assessment | The response assessment is redundant with the imaging findings. It should focus more on the clinical response rather than repeating imaging results. | CT abdomen/pelvis without contrast shows status post distal pancreatectomy with scattered pancreatic |
| P2 | Imaging_Plan.imaging_plan | The imaging plan is vague. It should specify the timing and reason for the next CT abdomen. | Within this limitation, no evidence of recurrent or metastatic disease in abdomen or pelvis. |

*Extraction summary*: Most fields are clean, but there are minor issues with the summary of the visit, stage description, treatment changes, response assessment, and imaging plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 79 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma with metastatic disease to liver
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | current_meds | The field is empty, but the note mentions 'gemcitabine, irinotecan, oxaliplatin, leucovorin'. | phase III evidence supports either ***** (biweekly ***** 5-*****, leucovorin, irinotecan, and oxalip |
| P2 | Treatment_Goals | The field states 'palliative', but the note suggests a goal of achieving a deep and durable remission. |  |
| P2 | Lab_Results | The field includes 'Hemoglobin 14.0, Hematocrit 41.0, Platelet Count 166, Int'l Normaliz Ratio 1.0', which are not mentioned in the note. | Most recent labs notable for the following: Lab Results Component Value Date WBC Count 5.8 05/02/202 |

*Extraction summary*: Most fields are clean, but there are minor issues with current_meds, Treatment_Goals, and Lab_Results.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | The term 'adenocarcinoma' is used without further explanation, which might be confusing for an 8th-grade reading level. | You have been diagnosed with pancreatic adenocarcinoma (cancer that started in g |
| P2 | While 'CA 19-9' is not flagged for explanation, the term 'tumor marker' might still be too technical for an 8th-grade reading level. | Your CA 19-9 (a tumor marker) level is elevated at 852. |
| P2 | The list of drug names might be overwhelming and confusing for an 8th-grade reading level. | You will start a combination of chemotherapy drugs called a chemotherapy combina |
| P2 | The term 'MRI study' might be too technical for an 8th-grade reading level. | An MRI study will be conducted before starting treatment. |
| P2 | Terms like 'germline testing', 'hereditary predisposition', and 'molecular testing' might be too technical for an 8th-grade reading level. | Germline testing will be done to assess for any hereditary predisposition to can |

*Letter summary*: The letter contains minor readability issues that could be improved for an 8th-grade reading level.

---

## ROW 82 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Stage IV (metastatic to liver and lung)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medication (abraxane). | Started ***** abraxane C1D1 08/03/18 |

*Extraction summary*: One minor issue found in Current_Medications.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 84 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Current medications should include both atezolizumab and cobimetinib. | Now midway through cycle #2 of treatment on the crossover arm of the same [REDACTED] trial consistin |
| P2 | Treatment_Changes | Incomplete. Should mention both atezolizumab and cobimetinib. | Switched to the combination of atezolizumab, a PD-L1 inhibitor (administered on a q2 weekly schedule |
| P2 | Treatment_Goals | Inaccurate. Goals should be 'palliative' rather than 'palliative'. | Goals of treatment are not explicitly stated, but context suggests palliative. |
| P2 | Genetic_Testing_Plan | Inaccurate. 'pd-l1' is not a valid value for genetic testing plan. | No specific genetic testing plan mentioned. |

*Extraction summary*: Most fields are clean, but there are minor issues with completeness and classification in medication and genetic testing fields.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 87 — ⚠️ ISSUES

**Type**: Pancreatic neuroendocrine tumor, well-differentiated
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing octreotide, which is a cancer-related medication. | octreotide (SANDOSTATIN *****) 30 mg every 30 (thirty) days. |
| P2 | Treatment_Changes | Supportive medications listed are incomplete. 'nystatin (MYCOSTATIN) ointment' is not relevant to cancer treatment. | No specific mention of supportive medications related to cancer treatment. |
| P2 | Treatment_Goals | The goal 'palliative' is correct but could be more precise given the context of ongoing management and monitoring. | The patient is being managed with ongoing monitoring and treatment. |
| P2 | Response_Assessment | The wording 'some minimal progression' is slightly imprecise. The note suggests 'slow PD'. | My interpretation is that there is slow PD v December 2016. |
| P2 | Medication_Plan | The plan mentions 'metformin', which is not a cancer-related medication. | Continue Everolimus 10 mg daily. Continue octreotide. If progression, could consider temozolomide, [ |
| P2 | Procedure_Plan | The plan mentions 'monitoring triglycerides quarterly', which is not directly related to cancer treatment. | Continue to monitor Q 3 months. |
| P2 | Imaging_Plan | The plan mentions '[REDACTED] dotatate MRI', which is incomplete. | Review at [REDACTED] dotatate MRI. |
| P2 | Lab_Plan | The plan mentions 'q 4 mo TSH on everolimus', which is incomplete. | q 4 mo TSH on everolimus November/November 2017 |

*Extraction summary*: Most fields are clean, but there are minor issues with completeness and precision in several fields.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 90 — ⚠️ ISSUES

**Type**: Primary pancreatic neuroendocrine tumor; BRAF-mutant metastatic melanoma
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medications (dabrafenib and trametinib). | continues on clinical trial, taking intermittent dabrafenib +***** ***** then trametinib alone ***** |
| P2 | Treatment_Changes | Missing recent changes related to dabrafenib and trametinib. | continues on clinical trial, taking intermittent dabrafenib +***** ***** then trametinib alone ***** |
| P2 | Treatment_Goals | Goals of treatment should include both palliative and symptom management. | Patient has multiple hyperattenuating liver lesions, two of which are new from 05/17/2015, suspiciou |
| P2 | Medication_Plan | Includes non-cancer-related medications (denosumab, everolimus, sunitinib). | Consider denosumab or zometa for bone disease. |
| P2 | Imaging_Plan | Should include regular PET/CT scans per clinical trial. | Per dr ***** |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications, treatment goals, and imaging plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. | Your glucose level was high at /dL, which is higher than normal. |
| P2 | Incomplete sentence with missing critical information. | Your dose of octreotide was reduced for four days, then increased for four days, |

*Letter summary*: The letter contains incomplete sentences that need to be corrected for clarity and completeness.

---

## ROW 91 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas, moderately differentiated
**Stage**: Resected with 8 of 23 lymph nodes positive

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions the patient has completed neoadjuvant therapy with gemcitabine and Abraxane. | He has completed 6 cycles of therapy. His last 2 cycles were given with alternate week schedule usin |
| P2 | Treatment_Changes | The field is empty, but the note mentions the patient has completed neoadjuvant therapy and had a surgical resection. | He has completed 6 cycles of therapy. He was taken to surgery on 11/27/2018. |
| P2 | Treatment_Goals | The field states 'curative', but the note suggests ongoing monitoring for recurrence, which aligns more with 'surveillance'. | As long as he is asymptomatic, we will watch this as hope that it represents delayed post op changes |
| P2 | Response_Assessment | The field states 'stable disease', but the note suggests possible local recurrence, which is more specific. | He may well have local recurrence but with the current coronavirus crisis, it will be difficult to w |
| P2 | Imaging_Plan | The field states 'No imaging planned', but the note suggests ongoing monitoring, which might include future imaging. | As long as he is asymptomatic, we will watch this as hope that it represents delayed post op changes |

*Extraction summary*: Most fields are clean, but there are minor issues regarding medication status, treatment goals, response assessment, and imaging plans.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 92 — ⚠️ ISSUES

**Type**: Moderately differentiated pancreatic adenocarcinoma with perineural and lymphova
**Stage**: Originally borderline resectable, now metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Type_of_Cancer | The extracted type of cancer is overly specific and not directly stated in the note. | The note mentions 'moderately differentiated adenocarcinoma' but does not specify 'perineural and ly |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The extracted stage is imprecise and does not accurately reflect the note. | The note states 'borderline resectable' initially and now 'metastatic', but the extracted 'originall |
| P2 | Lab_Results.lab_summary | The lab summary includes redacted values which are not present in the note. | The note does not provide specific lab values except for CA 19-9. |
| P2 | Clinical_Findings.findings | The extracted findings are incomplete and miss key details from the note. | The note provides detailed imaging findings and physical exam results that are not fully captured. |
| P2 | Treatment_Changes.recent_changes | The field is empty, but the note mentions recent treatment changes. | The note discusses resuming chemotherapy and recent surgeries. |
| P2 | Treatment_Goals.goals_of_treatment | The goal is labeled as 'palliative', but the note suggests ongoing management with potential for further treatment. | The note indicates ongoing treatment and future clinical trial possibilities. |
| P2 | Response_Assessment.response_assessment | The response assessment is incomplete and misses key details from the note. | The note provides detailed imaging findings and response assessments that are not fully captured. |
| P2 | Medication_Plan.medication_plan | The plan mentions trametinib, which is not a current medication but a future consideration. | Trametinib is mentioned as a future clinical trial possibility, not a current medication. |
| P2 | Therapy_plan.therapy_plan | The plan mentions trametinib, which is not a current medication but a future consideration. | Trametinib is mentioned as a future clinical trial possibility, not a current medication. |
| P2 | follow_up_next_visit.Next clinic visit | The next visit is described as 'for repeat imaging', but the note specifies '2-3 months for repeat imaging'. | The note specifies the timing of the next visit. |

*Extraction summary*: Several fields contain minor issues related to completeness and precision, but no major errors.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 98 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine and Abraxane) | We initially saw her about 2 months ago. We recommended therapy with gemcitabine and Abraxane. |
| P2 | Treatment_Changes | Supportive medications listed are incomplete | She was having a lot of difficulty with nausea and vomiting, early satiety and low caloric intake. W |
| P2 | Lab_Plan | Incorrect classification, should be under Therapy_plan | Once we can get her albumin up to 2 or better, we can resume her chemotherapy. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications and incomplete supportive medications. Additionally, 'Lab_Plan' is misclassified.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

